

Research Compliance Activity and Turn-Around-Time (TAT) Summary Report
Fiscal Year 2019 (7/1/2018 to 6/30/2019)

TAT calculated from submission date to date of approval. TAT not calculated for continuing reviews.

Institutional Biosafety Committee (IBC) - Bloomington										
	Q1 TAT		Q2 TAT		Q3 TAT		Q4 TAT		FY-END TAT	
	Mean	Median	Mean	Median	Mean	Median	Mean	Median	Mean	Median
Full Board	Full Board									
New Studies - Full Board (to review)	17.0	15.5	16.0	16.0	32.0	32.0	32.5	32.5	24.4	24.0
New Studies - Full Board (to approval)	26.8	25.0	44.7	36.0	40.0	40.0	34.0	34.0	36.4	33.8
Exempt	Exempt									
New Studies - Exempt (to determination)	23.8	22.5	10.5	10.5	15.3	9.0	18.0	3.0	16.9	11.3
Amendments	Amendments									
Amendments - Minor	4.0	1.0	5.6	3.0	2.1	1.0	2.3	1.0	3.5	1.5
Amendments - Major	52.5	52.5	n/a	n/a	27.2	20.0	35.0	35.0	38.2	35.8

*Note: TAT includes a "pre-review" time frame occurring prior to full committee meeting.

Area Activities/Throughput (T)	Q1 (Jul-Sep)			Q2 (Oct-Dec)			Q3 (Jan-Mar)			Q4 (Apr-Jun)		
	Received	Completed	Throughput/ % Backlogged	Received	Completed	Throughput/ % Backlogged	Received	Completed	Throughput/ % Backlogged	Received	Completed	Throughput/ % Backlogged
New Studies - Full Board	3	4	1	2	3	1	3	3	0	0	3	3
New Studies - Exempt	7	6	-1 (14.3%)	4	2	-2 (50.0%)	5	5	0	1	2	1
Amendments - Minor	52	51	-1 (1.9%)	39	41	2	42	45	3	59	51	-8 (13.6%)
Amendments - Major	0	1	1	5	0	-5 (100.0%)	1	5	4	3	1	-2 (66.7%)
Continuing Reviews	31	28	-3 (9.7%)	28	27	-1 (3.6%)	24	28	4	42	50	8
TOTAL	93	90	-3 (3.2%)	78	73	-5 (6.4%)	75	86	11 (-14.7%)	105	107	2 (-1.9%)

Area Training Activities	Q1 (Jul-Sep)	Q2 (Oct-Dec)	Q3 (Jan-Mar)	Q4 (Apr-Jun)	FY TOTALS
Presentations (# of events)	0	0	0	0	0

Reportable Events/Activities	Q1 (Jul-Sep)	Q2 (Oct-Dec)	Q3 (Jan-Mar)	Q4 (Apr-Jun)	FY TOTALS
Immediate OBA Report	0	0	0	0	0
30 Day OBA Report	2	0	0	0	2
Lab Accident/Injury/Exposure	0	1	1	0	2

Reporting Agency: NIH Office of Biotechnology Activities (OBA)